Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition
Neuroscience drug developer Lundbeck is expanding its scope to epilepsy via the $2.6 billion acquisition of Longboard Pharmaceuticals, a company ...
Neuroscience drug developer Lundbeck is expanding its scope to epilepsy via the $2.6 billion acquisition of Longboard Pharmaceuticals, a company ...
A University of Texas at Dallas chemist and his colleagues have developed a new chemical reaction that will allow researchers ...
Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating blood disorder, is being acquired by Recordati in ...
Researchers have developed a new drug that holds promise in Alzheimer's treatment by blocking tau-build-up, acting at two regions of ...
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval ...
Schizophrenia is currently treated with older medications with limited efficacy and troublesome side effects that lead many patients to stop ...
The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. ...
Researchers have developed TxGNN, an AI-powered model that outperforms existing methods by predicting treatments for diseases lacking approved therapies, using ...
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Hello, happy ...
An experimental GLP-1 obesity drug from Terns Pharmaceuticals led to a 5.5% reduction in body weight in a small study, ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.